Peptide Receptor Radionuclide Therapy (PRRT) Market to Reach USD 1,838.9 Million by 2036 Amid Rising Adoption of Targeted Radionuclide Oncology Treatments

NEWARK, Del., USA | JUNE 02, 2026 - According to the latest analysis by Future Market Insights, the global Peptide Receptor Radionuclide Therapy (PRRT) Market is experiencing robust growth, fueled by expanding clinical adoption of targeted radionuclide therapies, increasing diagnosis rates of neuroendocrine tumours (NETs), and growing investments in nuclear medicine infrastructure worldwide. As oncology treatment paradigms increasingly shift toward precision medicine and theranostic approaches, PRRT is emerging as a highly effective therapeutic modality for somatostatin receptor-positive tumours, creating significant opportunities across hospitals, cancer treatment centers, and radiopharmaceutical manufacturers.

* Featured Snippet: Key Market Insights

• Market Size (2025): USD 749.6 Million

• Market Value (2026): USD 813.3 Million

• Forecast Value (2036): USD 1,838.9 Million

• CAGR (2026-2036): 8.5%

• Incremental Opportunity: USD 1,025.57 Million

• Top Growth Markets: South Korea and Europe

• Key Drivers: Expanding clinical evidence for PRRT, regulatory approvals for lutetium-177 therapies, increasing NET diagnosis rates, growth in theranostics

• Leading Component Segment: Regulatory Peptide

• Leading Indication Segment: Gastrointestinal Neuroendocrine Tumours

👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-10376

Market Overview: Precision Oncology and Theranostics Fuel Market Expansion

The peptide receptor radionuclide therapy (PRRT) market is projected to grow from USD 813.3 million in 2026 to approximately USD 1,838.9 million by 2036, registering a CAGR of 8.5% during the forecast period.

Market growth is being driven by increasing acceptance of targeted radionuclide therapies within oncology treatment protocols, expanding regulatory approvals, and rising utilization of molecular imaging technologies that improve patient identification and treatment selection.

PRRT has emerged as a highly specialized treatment option for neuroendocrine tumours, combining targeted peptide delivery systems with therapeutic radionuclides to selectively destroy cancer cells while minimizing damage to healthy tissues. The growing integration of diagnostic imaging and therapeutic interventions under the theranostic model is further accelerating market adoption globally.

Key Market Drivers

1. Expanding Clinical Evidence Supporting PRRT Adoption

Increasing clinical validation of PRRT efficacy continues to strengthen market demand.

Key growth contributors include:

• Positive progression-free survival outcomes in NET patients

• Expanding clinical trial activity for new indications

• Growing physician confidence in targeted radionuclide therapies

• Inclusion of PRRT in oncology treatment guidelines

Clinical evidence continues supporting PRRT as an effective treatment alternative for patients with advanced or inoperable neuroendocrine tumours.

2. Regulatory Approvals and Reimbursement Expansion

Growing regulatory support is creating favorable market conditions.

This trend is supported by:

• FDA and EMA approvals for lutetium-177-DOTATATE therapies

• Expanding reimbursement frameworks

• Increased healthcare provider adoption

• Greater accessibility to specialized treatment centers

Structured reimbursement pathways are helping improve patient access while encouraging healthcare institutions to expand nuclear medicine capabilities.

3. Growing Neuroendocrine Tumour Diagnosis Rates

Advancements in imaging and biomarker technologies are increasing identification of eligible patients.

This trend is reinforced by:

• Improved somatostatin receptor imaging techniques

• Rising awareness of neuroendocrine tumours

• Expansion of precision diagnostics programs

• Growing oncology screening initiatives

As more patients are diagnosed earlier, demand for targeted treatment options such as PRRT is expected to increase significantly.

👉 Speak to Analyst: Customize insights for your business strategy: https://www.futuremarketinsights.com/customization-available/rep-gb-10376

Segment Insights

Regulatory Peptide Leads Component Segment Demand

The Regulatory Peptide segment is expected to account for 35.0% of total component revenue in 2026 due to:

• Critical role in targeted radionuclide delivery

• Strong clinical adoption of somatostatin analogs

• Proven effectiveness in receptor-specific tumour targeting

• Continued innovation in peptide engineering

Regulatory peptides remain the foundation of PRRT treatment by enabling highly selective delivery of therapeutic isotopes to tumour cells.

Gastrointestinal Neuroendocrine Tumours Remain Largest Indication Segment

Gastrointestinal Neuroendocrine Tumours are projected to account for 42.0% of total indication demand in 2026 owing to:

• Largest diagnosed patient population

• High prevalence of somatostatin receptor expression

• Strong clinical evidence supporting PRRT efficacy

• Established regulatory approvals for GI-NET treatment

This indication continues representing the largest commercial opportunity within the global PRRT market.

Hospitals Dominate End-User Demand

Hospitals are expected to account for 52.0% of market revenue in 2026 due to:

• Availability of nuclear medicine infrastructure

• Radiation safety and isotope handling capabilities

• Access to multidisciplinary oncology teams

• Ability to administer complete PRRT treatment cycles

Hospitals remain the primary treatment setting for PRRT administration worldwide.

👉 Explore the Latest Healthcare Industry Analysis Now:
https://www.futuremarketinsights.com/industry-analysis/healthcare

Regional Insights

South Korea

South Korea is projected to register the fastest growth with a CAGR of 8.9% through 2036, driven by:

• Expansion of nuclear medicine facilities

• Government investment in oncology infrastructure

• Growing neuroendocrine tumour diagnosis rates

• Increased adoption of advanced radiopharmaceutical therapies

The country continues strengthening its position as a leading Asia-Pacific hub for nuclear medicine innovation.

Europe

Europe is anticipated to expand at a CAGR of 8.5% owing to:

• Established nuclear medicine infrastructure

• Comprehensive NET treatment guidelines

• Strong reimbursement support

• Widespread adoption of theranostic approaches

The region remains one of the largest and most mature PRRT markets globally.

United States

The United States market is projected to grow at a CAGR of 8.3% through 2036.

Growth continues to be supported by:

• FDA-approved PRRT therapies

• Established reimbursement pathways

• High concentration of specialized treatment centers

• Strong clinical research activity

The country continues leading innovation and commercialization efforts within the global PRRT ecosystem.

Japan

Japan is expected to grow at a CAGR of 8.2% due to:

• Leadership in nuclear medicine technologies

• Growing radiopharmaceutical research activities

• Expanding oncology treatment capabilities

• Improved patient identification programs

Japan remains a key market for future PRRT advancements.

Technology and Research Trends

The PRRT market is evolving through advancements in:

• Lutetium-177-based radiopharmaceutical therapies

• Next-generation peptide targeting agents

• Improved radionuclide production technologies

• Theranostic treatment platforms

• Enhanced molecular imaging and treatment monitoring systems

Manufacturers are increasingly focusing on improving treatment efficacy, expanding indication coverage, and strengthening radiopharmaceutical supply chains to support growing demand.

👉 Get Full Report Access for Detailed Analysis: https://www.futuremarketinsights.com/reports/peptide-receptor-radionuclide-therapy-prrt-market

Challenges in the Market

Radiopharmaceutical Supply Chain Constraints

The market continues facing challenges from:

• Limited global isotope production capacity

• Dependence on nuclear reactor infrastructure

• Supply chain complexity for therapeutic radionuclides

• Long lead times for production facility expansion

Manufacturers and healthcare systems continue investing in production infrastructure to improve supply reliability.

Specialized Infrastructure Requirements

Additional challenges include:

• High capital investment requirements

• Limited number of PRRT-qualified treatment centers

• Need for trained nuclear medicine personnel

• Strict radiation safety regulations

Healthcare providers continue expanding specialized treatment capabilities to improve patient access.

Opportunities: Expansion Beyond Traditional Neuroendocrine Tumours

The market is unlocking new opportunities through:

• Expansion into pancreatic and lung NET indications

• Development of next-generation radionuclide therapies

• Growth of theranostic oncology programs

• Increasing personalized medicine initiatives

• Rising investment in radiopharmaceutical innovation

Organizations capable of expanding treatment indications while improving isotope availability are expected to strengthen their long-term market position.

Competitive Landscape

The PRRT market remains moderately consolidated, with leading companies focusing on radiopharmaceutical innovation, isotope production, and targeted oncology therapeutics.

Leading Companies

• Novartis AG (Advanced Accelerator Applications)

• Curium Pharma

• ITM Isotope Technologies Munich SE

• Eckert & Ziegler AG

• Fusion Pharmaceuticals Inc.

These companies continue investing in clinical development programs, isotope manufacturing capabilities, and next-generation targeted radionuclide therapies to expand their competitive positioning.

👉 Unlock high-growth opportunities with FMI's niche business market insights: https://www.futuremarketinsights.com/industry-analysis

Recent Developments

• In 2025, Novartis AG reported positive Phase III clinical trial results supporting expanded indications for lutetium-177-DOTATATE therapy.

• In 2025, ITM Isotope Technologies Munich SE advanced its next-generation lutetium-177-based PRRT candidate into late-stage clinical development.

• Several radiopharmaceutical manufacturers expanded isotope production capacity investments to address growing global demand for therapeutic radionuclides.

Conclusion: Targeted Radionuclide Therapies to Transform Oncology Treatment Landscape

The peptide receptor radionuclide therapy (PRRT) market is rapidly evolving as targeted radionuclide treatments gain recognition within mainstream oncology care. Rising clinical evidence, expanding regulatory support, growing neuroendocrine tumour diagnosis rates, and continued innovation in theranostic medicine are expected to sustain strong market growth through 2036.

As healthcare systems increasingly embrace precision oncology approaches, organizations with advanced radiopharmaceutical portfolios, reliable isotope supply capabilities, and strong clinical development pipelines are expected to lead the next phase of growth in the global PRRT industry.

* FAQs

1. How large is the PRRT market in 2026?

The global PRRT market is estimated at USD 813.3 million in 2026.

2. What will be the PRRT market size by 2036?

The market is projected to reach USD 1,838.9 million by 2036.

3. What growth rate is expected for the PRRT market?

The market is expected to grow at a CAGR of 8.5% from 2026 to 2036.

4. Which component segment leads the PRRT market?

Regulatory Peptide is expected to lead with a 35.0% market share in 2026.

5. Which indication segment dominates the PRRT market?

Gastrointestinal Neuroendocrine Tumours are expected to lead with a 42.0% market share in 2026.

* Have a Look at Related Research Reports on the Healthcare Domain

· Hormone Replacement Therapy Market - https://www.futuremarketinsights.com/reports/hormone-replacement-therapy-market

· Aquablation Therapy Market - https://www.futuremarketinsights.com/reports/aquablation-therapy-market

· In-vitro Human Models Market - https://www.futuremarketinsights.com/reports/in-vitro-human-models-market

· Electrophysiology Market - https://www.futuremarketinsights.com/reports/electrophysiology-market

· Endometriosis Treatment Market - https://www.futuremarketinsights.com/reports/endometriosis-treatment-market

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com

Future Market Insights is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Headquartered in Newark, with a global delivery center in Pune and offices in the United Kingdom and United Arab Emirates, FMI delivers actionable insights across industries including food & beverage, healthcare, chemicals, and consumer goods.

An ESOMAR-certified organization, FMI provides data-driven insights to support strategic decision-making for global businesses.

This release was published on openPR.